Product Development

CMC Process Development and Optimization

Advancing your biologics development

Alira Health CMC Team helps develop technical design for biotherapeutic production and optimize manufacturing processes.

We also provide additional support for small molecule therapeutics at every stage of production:
  • Antibody engineering and developability
  • Cell line development
  • Upstream development
  • Downstream development
  • Formulation development
  • Product and process characterization

Why choose Alira Health?

Alira Health is your partner in every stage of production, working closely with you to design, optimize and deliver advanced biologics. Our subject matter experts will:

  • Advise and support process development activities including antibody engineering and developability, creation of a highly productive cell line, upstream, downstream, and formulation development
  • Actively engage in planning for scale up and cGMP manufacture of drug substance and product, analytical method development and QC
  • Provide large molecule therapeutic development expertise including microbial, mammalian, and yeast cell expression systems
  • Leverage extensive experience with monoclonal antibodies and derivatives, including bispecifics, fusion proteins, and antibody drug conjugates
  • Deliver technical expertise and support for small molecule therapeutic development

Related news

Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)
Research & Development
Publications April 26, 2021
Recombinant Human Polyclonal Antibodies to Treat Disease
Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their(...)
Research & Development
News March 15, 2021
Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical
BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”
Advanced Analytics Regulatory Research & Development
News November 20, 2020
Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
Alira Health congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device toward clinical trials.(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.